RKI-1447 – 50 mg

Brand:
Cayman
CAS:
1342278-01-6
Storage:
-20
UN-No:
Non-Hazardous - /

RKI-1447 is an inhibitor of the Rho-associated kinases ROCK-I and II (IC50s = 14.5 and 6.2 nM, respectively) that functions by binding to the ATP binding site of the kinase.{27949} In cancer cells, RKI-1447 at a concentration of 100 nM has been found to suppress the activation of ROCK substrates myosin light chain (MLC)-2 and the MLC phosphatase PP1 regulatory subunit MYPT1 without effect on the phosphorylation of Akt, MEK, or S6 kinase.{27949} Furthermore, it can prevent ROCK-mediated migration, invasion, and anchorage-independent growth of MDA-MB-231 breast cancer cells (IC50 = 709 nM).{27949}  

 

SKU: - Category:

Description

A ROCK-I and II inhibitor (IC50s = 14.5 and 6.2 nM, respectively) that functions by binding to the ATP binding site of the kinase; suppresses the activation of ROCK substrates MLC-2 and the MLC phosphatase PP1 regulatory subunit MYPT1 at 100 nM in cancer cells


Formal name: N-[(3-hydroxyphenyl)methyl]-N’-[4-(4-pyridinyl)-2-thiazolyl]-urea

Synonyms: 

Molecular weight: 326.4

CAS: 1342278-01-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|ROCK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|ROCK Signaling||Research Area|Cell Biology|Cytoskeleton & Motor Proteins